Drugs / ADP-TILIL7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06204991 | Apr 2025 → Mar 2027 expected | melanoma | Inge Marie Svane | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADP-TILIL7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06204991 ↗ |
| Modality | Cell therapy | “novel generation of gene-modified tumor infiltrating lymphocytes (TILs)” NCT06204991 ↗ |
| Route | Intravenous | “reapplied to the patient via an intravenous infusion” NCT06204991 ↗ |
| Target | IL7 | “TILs will undergo transduction with the Interleukin-7 (IL-7) gene” NCT06204991 ↗ |